Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL

被引：8

作者：

Bachy, Emmanuel ^{[1
,2
]}

Salles, Gilles ^{[1
,2
,3
]}

机构：

[1] Hosp Civils Lyon, F-69495 Pierre Benite, France

[2] Univ Lyon 1, F-69495 Pierre Benite, France

[3] CNRS, UMR 5239, Lyon, France

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2011年 / 24卷 / 02期

关键词：

follicular lymphoma; autologous stem cell transplantation; rituximab; late toxicity; conditioning regimen; HIGH-DOSE THERAPY; NON-HODGKINS-LYMPHOMA; IBRITUMOMAB TIUXETAN RADIOIMMUNOTHERAPY; ACUTE MYELOGENOUS LEUKEMIA; TERM-FOLLOW-UP; SECONDARY MYELODYSPLASTIC SYNDROME; PROGRESSION-FREE SURVIVAL; ACUTE MYELOID-LEUKEMIA; REFRACTORY LOW-GRADE; BONE-MARROW;

D O I：

10.1016/j.beha.2011.03.001

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-dose therapy followed by autologous stem cell transplantation is widely accepted as salvage therapy for patients with relapsed aggressive lymphoma. In the pre-rituximab era, autologous stem cell transplantation had also been increasingly applied as a consolidation treatment for patients with indolent lymphoma in second or subsequent remission whereas controversies have emerged concerning its role in first line therapy from several randomized trials. Broad development and amazing efficacy of monoclonal antibody-based combination therapies for de novo or relapsing follicular lymphoma patients render previous conclusions outdated and underline the critical need for further phase III trials. This review focuses on available data from pre-rituximab and rituximab eras to help clarifying the precise role and timing of autologous stem cell transplantation among the current armamentarium for follicular lymphoma treatment. (C) 2011 Elsevier Ltd. All rights reserved.

引用

页码：257 / 270

页数：14

共 70 条

[1]

[Anonymous], J CLIN ONCOL

[2] High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: Long-term clinical and molecular follow-up [J].

Apostolidis, J ;

Gupta, RK ;

Grenzelias, D ;

Johnson, PWM ;

Pappa, VI ;

Summers, KE ;

Salam, A ;

Adams, K ;

Norton, AJ ;

Amess, JAL ;

Matthews, J ;

Bradburn, M ;

Lister, TA ;

Rohatiner, AZS .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (03) :527-536

[3] Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma [J].

Arcaini, L. ;

Montanari, F. ;

Alessandrino, E. P. ;

Tucci, A. ;

Brusamolino, E. ;

Gargantini, L. ;

Cairoli, R. ;

Bernasconi, P. ;

Passamonti, F. ;

Bonfichi, M. ;

Zoli, V. ;

Bottelli, C. ;

Calatroni, S. ;

Troletti, D. ;

Merli, M. ;

Pascutto, C. ;

Majolino, I. ;

Rossi, G. ;

Morra, E. ;

Lazzarino, M. .

ANNALS OF ONCOLOGY, 2008, 19 (07) :1331-1335

[4] Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients [J].

Armitage, JO ;

Carbone, PP ;

Connors, JM ;

Levine, A ;

Bennett, JM ;

Kroll, S .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (05) :897-906

[5] INTENSIVE THERAPY WITH PERIPHERAL-BLOOD PROGENITOR-CELL TRANSPLANTATION IN 60 PATIENTS WITH POOR-PROGNOSIS FOLLICULAR LYMPHOMA [J].

BASTION, Y ;

BRICE, P ;

HAIOUN, C ;

SONET, A ;

SALLES, G ;

MAROLLEAU, JP ;

ESPINOUSE, D ;

REYES, F ;

GISSELBRECHT, C ;

COIFFIER, B .

BLOOD, 1995, 86 (08) :3257-3262

[6] Efficiency of in vivo purging with rituximab prior to autologous peripheral blood progenitor cell transplantation in B-cell non-Hodgkin's lymphoma:: a single institution study [J].

Belhadj, K ;

Delfau-Larue, MH ;

Elgnaoui, T ;

Beaujean, F ;

Beaumont, JL ;

Pautas, C ;

Gaillard, I ;

Kirova, Y ;

Allain, A ;

Gaulard, P ;

Farcet, JP ;

Reyes, F ;

Haioun, C .

ANNALS OF ONCOLOGY, 2004, 15 (03) :504-510

[7] Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab [J].

Bennett, JM ;

Kaminski, MS ;

Leonard, JP ;

Vose, JM ;

Zelenetz, AD ;

Knox, SJ ;

Horning, S ;

Press, OW ;

Radford, JA ;

Kroll, SM ;

Capizzi, RL .

BLOOD, 2005, 105 (12) :4576-4582

[8] High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol [J].

Brice, P ;

Simon, D ;

Bouabdallah, R ;

Bélanger, C ;

Haïoun, C ;

Thieblemont, C ;

Tilly, H ;

Harousseau, JL ;

Doyen, C ;

Martin, C ;

Brousse, N ;

Solal-Céligny, P .

ANNALS OF ONCOLOGY, 2000, 11 (12) :1585-1590

[9] Peripheral Blood Stem Cell Mobilization After Bendamustine Containing Chemotherapy in Indolent Lymphomas Is Possible. Results From the Phase III Study of B-R Vs. CHOP-R (NHL 1-2003 trial) of the StiL (Study group indolent Lymphomas, Germany) [J].

Burchardt, Christoph Alexander ;

Brugger, Wolfram ;

Maschmeyer, Georg ;

Kofahl-Krause, Dorothea ;

Fischer, Lars ;

Roller, Fritz ;

Barth, Juergen ;

Rummel, Mathias J. .

BLOOD, 2009, 114 (22) :1048-1049

[10]

COLOMBAT P, 1994, BONE MARROW TRANSPL, V13, P157

← 1 2 3 4 5 6 7 →